---
title: "CAPR DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCAPR"
description: "NEW YORK, Aug. 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. CAPR between October 9, 2024 and J"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255313980.md"
published_at: "2025-08-30T13:36:39.000Z"
---

# CAPR DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCAPR

> NEW YORK, Aug. 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. CAPR between October 9, 2024 and July 10, 2025, both dates inclusive ( the "Class Period" ) , of the important September 15, ...

NEW YORK, Aug. 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. CAPR between October 9, 2024 and July 10, 2025, both dates inclusive ( the "Class Period" ) , of the important September 15, ...

### Related Stocks

- [CAPR.US - Capricor Therap](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Capricor Therapeutics 發佈投資者演示，重點介紹杜氏肌營養不良症項目和外泌體平台 | Capricor Therapeutics Inc. 發佈了一份投資者演示文稿，詳細介紹了其杜氏肌營養不良症治療項目 deramiocel 的最新進展。主要亮點包括完成了預許可檢查、HOPE-3 第三階段試驗的積極結果，以及計劃向 FDA  | [Link](https://longbridge.com/en/news/274992906.md) |
| Capricor 治療公司（納斯達克股票代碼：CAPR）的空頭頭寸減少了 69.4% | Capricor Therapeutics, Inc.（納斯達克代碼：CAPR）在 12 月份的空頭頭寸減少了 69.4%，賣空股份總計為 5,029,282 股。該股票開盤價為 29.29 美元，52 周最高價為 40.37 美元。分析師 | [Link](https://longbridge.com/en/news/270785955.md) |
| BUZZ-Capricor 股價上漲，因 FDA 要求提供更多數據但無需進行新的試驗以用於杜氏肌營養不良症療法 | Capricor Therapeutics 的股票在盤前交易中上漲 6.4%，至 25.90 美元，此前 FDA 要求提供其杜氏肌營養不良症治療藥物 deramiocel 的額外文件，但並未要求進行新的試驗。該公司計劃在 2 月份提交完整的 | [Link](https://longbridge.com/en/news/273099287.md) |
| FDA 要求提供更多 HOPE-3 數據以審查 Capricor 治療的 Deramiocel 的批准 | Capricor Therapeutics Inc. 正在應對其生物製品許可申請（Biologics License Application）中關於 Deramiocel 的監管挑戰，Deramiocel 是一種用於杜氏肌營養不良症的細胞療 | [Link](https://longbridge.com/en/news/273097591.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.